Ausio header

 

Business and Partnering Strategy

Ausio is seeking partners to co-develop and commercialize
AUS-131 for the following indications:photo

  • Vasomotor Symptoms (VMS) – the lead program for AUS-131 is treatment of VMS. A Phase 2a study in 169 patients has recently been completed.

  • Benign Prostatic Hyperplasia (BPH) – AUS-131 has progressed to Phase 2 clinical testing. Results are expected in 2015.

Osteoporosis, prostate cancer, neurodegenerative disease
and other licenses will be considered after further
clinical development.

 
   

Home Contact UsDirections